TCGA-A7-A13G-01B-04R-A22O-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 24
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.250
- MITOTIC_SPINDLE+0.130
- HEDGEHOG_SIGNALING+0.090
- TGF_BETA_SIGNALING+0.060
- SPERMATOGENESIS-0.040
- HEME_METABOLISM-0.060
- KRAS_SIGNALING_DN-0.070
- NOTCH_SIGNALING-0.080
- BILE_ACID_METABOLISM-0.100
- APICAL_SURFACE-0.150
Top 10 suppressed
- MYC_TARGETS_V2-0.640
- MYC_TARGETS_V1-0.630
- E2F_TARGETS-0.550
- OXIDATIVE_PHOSPHORYLATION-0.540
- MTORC1_SIGNALING-0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- UV_RESPONSE_UP-0.480
- CHOLESTEROL_HOMEOSTASIS-0.460
- DNA_REPAIR-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.450
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A0DC-01B-04R-A22O-07 | — | D | 0.938 |
| 2 | MDT-AP-3267 | Med | Medulloblastoma | 0.932 |
| 3 | ed8896f8-24ef-43a4-ace6-ed9353bd11c2 | — | — | 0.930 |
| 4 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.928 |
| 5 | TCGA-A7-A26E-01B-06R-A277-07 | — | D | 0.928 |
| 6 | AUR-AFUN-TTP1-A-1-0-R-A741-41 | — | D | 0.927 |
| 7 | 62454053-936d-4f19-8522-6219c47bdd1c | — | — | 0.926 |
| 8 | ERR2598056 | fetal | fetal | 0.925 |
| 9 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.917 |
| 10 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |